Does the media favor LQDA or MLYS?

In the previous week, Mineralys Therapeutics had 2 more articles in the media than Liquidia. MarketBeat recorded 18 mentions for Mineralys Therapeutics and 16 mentions for Liquidia. Mineralys Therapeutics' average media sentiment score of 1.02 beat Liquidia's score of 0.50 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LNTH or MLYS?

In the previous week, Mineralys Therapeutics had 7 more articles in the media than Lantheus. MarketBeat recorded 18 mentions for Mineralys Therapeutics and 11 mentions for Lantheus. Lantheus' average media sentiment score of 1.39 beat Mineralys Therapeutics' score of 1.02 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, MLYS or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mineralys Therapeutics N/A N/A -$154.65M -$4.24 N/A Belite Bio N/A N/A -$77.61M -$2.73 N/A

Is MLYS or BLTE more profitable?

Belite Bio's return on equity of -11.84% beat Mineralys Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mineralys Therapeutics N/A -57.97% -54.15% Belite Bio N/A -11.84% -11.62%

Does the media refer more to MLYS or BLTE?

In the previous week, Mineralys Therapeutics had 13 more articles in the media than Belite Bio. MarketBeat recorded 18 mentions for Mineralys Therapeutics and 5 mentions for Belite Bio. Mineralys Therapeutics' average media sentiment score of 1.02 beat Belite Bio's score of -0.08 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, MLYS or DFTX?

Definium Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mineralys Therapeutics N/A N/A -$154.65M -$4.24 N/A Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A

Is MLYS or DFTX more profitable?

Mineralys Therapeutics' return on equity of -57.97% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mineralys Therapeutics N/A -57.97% -54.15% Definium Therapeutics N/A -84.01% -63.66%

Does the media refer more to MLYS or DFTX?

In the previous week, Mineralys Therapeutics had 9 more articles in the media than Definium Therapeutics. MarketBeat recorded 18 mentions for Mineralys Therapeutics and 9 mentions for Definium Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.02 beat Definium Therapeutics' score of 0.73 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mineralys Therapeutics (MLYS) Competitors

$25.89 -0.45 (-1.71%)

As of 03:15 PM Eastern

Compare

MLYS vs. CRNX, LQDA, LNTH, BLTE, and DFTX

Should you buy Mineralys Therapeutics stock or one of its competitors? Mineralys Therapeutics's main competitors and comparable companies include Crinetics Pharmaceuticals (CRNX), Liquidia (LQDA), Lantheus (LNTH), Belite Bio (BLTE), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Mineralys Therapeutics compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

In the previous week, Mineralys Therapeutics had 10 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 18 mentions for Mineralys Therapeutics and 8 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.43 beat Mineralys Therapeutics' score of 1.02 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crinetics Pharmaceuticals presently has a consensus target price of $81.00, indicating a potential downside of 4.54%. Mineralys Therapeutics has a consensus target price of $49.33, indicating a potential upside of 90.55%. Given Mineralys Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Mineralys Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Mineralys Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Crinetics Pharmaceuticals' return on equity of -44.22% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Mineralys Therapeutics	N/A	-57.97%	-54.15%

Mineralys Therapeutics has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,168.84	-$465.32M	-$5.04	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Crinetics Pharmaceuticals has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Summary

Mineralys Therapeutics beats Crinetics Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Liquidia has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	40.54	-$68.92M	$1.37	52.34
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

In the previous week, Mineralys Therapeutics had 2 more articles in the media than Liquidia. MarketBeat recorded 18 mentions for Mineralys Therapeutics and 16 mentions for Liquidia. Mineralys Therapeutics' average media sentiment score of 1.02 beat Liquidia's score of 0.50 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.5% of Liquidia shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Liquidia has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Liquidia has a net margin of 30.74% compared to Mineralys Therapeutics' net margin of 0.00%. Liquidia's return on equity of 149.65% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Mineralys Therapeutics	N/A	-57.97%	-54.15%

Liquidia currently has a consensus price target of $98.08, indicating a potential upside of 36.78%. Mineralys Therapeutics has a consensus price target of $49.33, indicating a potential upside of 90.55%. Given Mineralys Therapeutics' higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Mineralys Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Liquidia beats Mineralys Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Lantheus has a net margin of 17.69% compared to Mineralys Therapeutics' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Mineralys Therapeutics	N/A	-57.97%	-54.15%

Lantheus has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.56B	4.23	$233.56M	$4.14	24.38
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

In the previous week, Mineralys Therapeutics had 7 more articles in the media than Lantheus. MarketBeat recorded 18 mentions for Mineralys Therapeutics and 11 mentions for Lantheus. Lantheus' average media sentiment score of 1.39 beat Mineralys Therapeutics' score of 1.02 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus currently has a consensus target price of $108.11, indicating a potential upside of 7.10%. Mineralys Therapeutics has a consensus target price of $49.33, indicating a potential upside of 90.55%. Given Mineralys Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Mineralys Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

99.1% of Lantheus shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Lantheus beats Mineralys Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Belite Bio?

Mineralys Therapeutics (NASDAQ:MLYS) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Mineralys Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.22, suggesting that its share price is 222% less volatile than the broader market.

In the previous week, Mineralys Therapeutics had 13 more articles in the media than Belite Bio. MarketBeat recorded 18 mentions for Mineralys Therapeutics and 5 mentions for Belite Bio. Mineralys Therapeutics' average media sentiment score of 1.02 beat Belite Bio's score of -0.08 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mineralys Therapeutics currently has a consensus target price of $49.33, indicating a potential upside of 90.55%. Belite Bio has a consensus target price of $205.80, indicating a potential upside of 29.71%. Given Mineralys Therapeutics' higher probable upside, research analysts clearly believe Mineralys Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Belite Bio's return on equity of -11.84% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-57.97%	-54.15%
Belite Bio	N/A	-11.84%	-11.62%

Belite Bio is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Summary

Mineralys Therapeutics beats Belite Bio on 7 of the 12 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Definium Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Mineralys Therapeutics presently has a consensus price target of $49.33, suggesting a potential upside of 90.55%. Definium Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 42.82%. Given Mineralys Therapeutics' higher possible upside, equities analysts plainly believe Mineralys Therapeutics is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

Mineralys Therapeutics' return on equity of -57.97% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-57.97%	-54.15%
Definium Therapeutics	N/A	-84.01%	-63.66%

In the previous week, Mineralys Therapeutics had 9 more articles in the media than Definium Therapeutics. MarketBeat recorded 18 mentions for Mineralys Therapeutics and 9 mentions for Definium Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.02 beat Definium Therapeutics' score of 0.73 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Mineralys Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

Summary

Mineralys Therapeutics beats Definium Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Mineralys Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLYS vs. The Competition

Export

Metric	Mineralys Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.29B	$12.42B	$7.30B	$12.76B
Dividend Yield	N/A	2.61%	2.53%	10.79%
P/E Ratio	-6.11	783.00	272.85	24.16
Price / Sales	N/A	761.36	627.65	98.32
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	4.16	12.06	13.16	6.24
Net Income	-$154.65M	$2.83B	$3.47B	$348.07M
7 Day Performance	-3.93%	1.99%	1.31%	0.63%
1 Month Performance	-3.07%	6.10%	8.67%	4.84%
1 Year Performance	71.34%	7.94%	26.14%	16.90%

Mineralys Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLYS Mineralys Therapeutics	2.953 of 5 stars	$25.89 -1.7%	$49.33 +90.5%	+78.7%	$2.29B	N/A	N/A	28	News Coverage Positive News Insider Trade Analyst Revision
CRNX Crinetics Pharmaceuticals	1.7532 of 5 stars	$84.78 +0.0%	$81.00 -4.5%	+182.0%	$8.99B	$42.16M	N/A	210	Positive News
LQDA Liquidia	4.3126 of 5 stars	$73.54 -5.4%	$98.08 +33.4%	+168.5%	$6.58B	$450.91M	53.65	50	Insider Trade
LNTH Lantheus	4.1488 of 5 stars	$100.50 -0.4%	$108.11 +7.6%	+79.6%	$6.56B	$1.54B	24.28	1,193	Positive News
BLTE Belite Bio	3.0398 of 5 stars	$163.64 +0.3%	$205.80 +25.8%	+154.1%	$6.56B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLYS) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. CRNX, LQDA, LNTH, BLTE, and DFTX

How does Mineralys Therapeutics compare to Crinetics Pharmaceuticals?

Summary

How does Mineralys Therapeutics compare to Liquidia?

Summary

How does Mineralys Therapeutics compare to Lantheus?

Summary

How does Mineralys Therapeutics compare to Belite Bio?

Summary

How does Mineralys Therapeutics compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. CRNX, LQDA, LNTH, BLTE, and DFTX

How does Mineralys Therapeutics compare to Crinetics Pharmaceuticals?

Does the media favor CRNX or MLYS?

Do analysts prefer CRNX or MLYS?

Is CRNX or MLYS more profitable?

Which has better earnings and valuation, CRNX or MLYS?

Do institutionals & insiders believe in CRNX or MLYS?

Which has more volatility & risk, CRNX or MLYS?

Summary

How does Mineralys Therapeutics compare to Liquidia?

Which has stronger valuation and earnings, LQDA or MLYS?

Does the media favor LQDA or MLYS?

Do insiders & institutionals believe in LQDA or MLYS?

Which has more volatility and risk, LQDA or MLYS?

Is LQDA or MLYS more profitable?

Do analysts recommend LQDA or MLYS?

Summary

How does Mineralys Therapeutics compare to Lantheus?

Is LNTH or MLYS more profitable?

Which has preferable earnings and valuation, LNTH or MLYS?

Which has more volatility and risk, LNTH or MLYS?

Does the media favor LNTH or MLYS?

Do analysts rate LNTH or MLYS?

Do institutionals & insiders hold more shares of LNTH or MLYS?

Summary

How does Mineralys Therapeutics compare to Belite Bio?

Which has more volatility & risk, MLYS or BLTE?

Does the media refer more to MLYS or BLTE?

Do analysts recommend MLYS or BLTE?

Do institutionals and insiders believe in MLYS or BLTE?

Is MLYS or BLTE more profitable?

Which has higher earnings and valuation, MLYS or BLTE?

Summary

How does Mineralys Therapeutics compare to Definium Therapeutics?

Do analysts recommend MLYS or DFTX?

Is MLYS or DFTX more profitable?

Does the media refer more to MLYS or DFTX?

Which has better valuation and earnings, MLYS or DFTX?

Do institutionals and insiders hold more shares of MLYS or DFTX?

Which has more risk & volatility, MLYS or DFTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools